Phorbol myristate acetate suppresses breast cancer cell growth via down-regulation of P-Rex1 expression

References

[1] Barboule N, Lafon C, Chadebech P, Vidal S, Valette A (1999) Involvement of p21 in the PKC-induced regulation of the G2/M cell cycle transition. FEBS Lett 444:32–37

[2] Fortino V, Torricelli C, Capurro E, Sacchi G, Valacchi G, Maioli E (2008) Antiproliferative and survival properties of PMA in MCF-7 breast cancer cell. Cancer Invest 26:13–21

[3] Griner EM, Kazanietz MG (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev 7:281–294

[4] Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

[5] Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, Burnstein KL (2004) Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21 (CIP1) levels in androgen-independent human prostate cancer cells. Oncogene 23:5513–5522

[6] Montero JC, Seoane S, Ocaña A, Pandiella A(2011) P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene 30:1059–1071

[7] Montero JC, Seoane S, Pandiella A (2013) Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cell Signal 25:2281–2289

[8] Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, Merajver SD (2005) Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 65:8366–8371

[9] Qin J, Xie Y, Wang B, Hoshino M, Wolff DW, Zhao J, Scofield MA, Dowd FJ, Lin MF, Tu Y (2009) Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene 28:1853–1863

[10] Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E (2000) Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19:3013–3020

[11] Smith M, Procter RD, Gelber S, Guillaume A, Feyereislova M, Dowsett A, Goldhirsch M, Untch G, Mariani J, Baselga J (2007) 2-year follow-up of trastuzumab after adjuvant chemother-apy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36

[12] Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H (2010) Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 40:877–892

[13] Urtreger AJ, Kazanietz MG, de Kier Bal, Joffé ED (2012) Contribu-tion of individual PKC isoforms to breast cancer progression. IUBMB Life 64:18–26

[14] Welch HC, Coadwell WJ, Ellson CD, Ferguson GJ, Andrews SR, Erdjument-Bromage H, Tempst P, Hawkins PT, Stephens LR (2002) P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108:809–821

[15] Zhao Y, Wang Z, Jiang Y, Yang C (2011) Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells. Cancer Lett 313:54–63

RIGHTS & PERMISSIONS

2016 The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn